Archives: : Small Molecule

AI in Drug Discovery 2022 event (14-15 Mar, London)

  • on December 16, 2021

Mar 2022 - Intellegens is speaking at the AI in Drug Discovery event in London.

Read more

Alchemite™ machine learning identifies potential antimalarial drug compound

  • on November 17, 2021

With Optibrium and Open Source Malaria | Now published in the Journal of Medicinal Chemistry

Read more

Alchemite™ validated for global pharma data in peer-reviewed study

  • on June 29, 2021

Read more

Optimising kinase profiling programs with Optibrium and Genentech

  • on June 2, 2021

Optibrium and Genentech - drug discovery | Accurate models despite sparse data

Read more

Innovate UK Funded Project Produces Next-Generation AI Drug Discovery Platform

  • on December 3, 2020

Read more

Predicting pharmacokinetics with Optibrium and AstraZeneca

  • on November 11, 2020

Optibrium and AstraZeneca - drug discovery | Successfully predicts pharmacokinetics

Read more

Launch of Cerella, a novel AI platform for active learning in drug discovery

  • on November 2, 2020

Read more

Imputing heterogeneous drug discovery data

  • on June 22, 2020

Read more

Imputation versus prediction for drug discovery

  • on April 6, 2020

Read more
Anopheles mosquito

Optibrium and Intellegens achieve further success in Open Source Malaria initiative with in vitro validation of in silico generated compound

  • on April 1, 2020

Read more

Drug Discovery: Novel deep neural network imputation predicts bioactivity from sparse data

  • on January 16, 2020

Read more

Intellegens and Optibrium celebrate success in global challenge to find antimalarial compounds

  • on December 10, 2019

Read more